These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 14511612)

  • 1. Prognostic significance of bcl-2 expression in resected pN2 non-small cell lung cancer.
    Tomita M; Matsuzaki Y; Edagawa M; Shimizu T; Hara M; Onitsuka T
    Eur J Surg Oncol; 2003 Oct; 29(8):654-7. PubMed ID: 14511612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological prognostic factors for early stage completely resected non-small cell lung cancer.
    Cagini L; Monacelli M; Giustozzi G; Moggi L; Bellezza G; Sidoni A; Bucciarelli E; Darwish S; Ludovini V; Pistola L; Gregorc V; Tonato M
    J Surg Oncol; 2000 May; 74(1):53-60. PubMed ID: 10861611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.
    Ishida H; Irie K; Itoh T; Furukawa T; Tokunaga O
    Cancer; 1997 Sep; 80(6):1034-45. PubMed ID: 9305703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Di Carlo L; Semeraro A; Daddi G; Darwish S; Stocchi L; Tofanetti FR; Bellezza G; Sidoni A; Tognellini R; Crinò L; Tonato M
    Tumori; 2008; 94(3):398-405. PubMed ID: 18705409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers.
    Grossi F; Loprevite M; Chiaramondia M; Ceppa P; Pera C; Ratto GB; Serrano J; Ferrara GB; Costa R; Boni L; Ardizzoni A
    Eur J Cancer; 2003 Jun; 39(9):1242-50. PubMed ID: 12763212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship of Fas, FasL, p53 and bcl-2 expression in human non-small cell lung carcinomas.
    Li Y; Xu KP; Jiang D; Zhao J; Ge JF; Zheng SY
    Int J Clin Exp Pathol; 2015; 8(11):13978-86. PubMed ID: 26823709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Skip metastasis in nonsmall cell lung carcinoma: predictive markers and isolated tumor cells in N1 lymph nodes.
    Prenzel KL; Baldus SE; Mönig SP; Tack D; Sinning JM; Gutschow CA; Grass G; Schneider PM; Dienes HP; Hölscher AH
    Cancer; 2004 May; 100(9):1909-17. PubMed ID: 15112272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive survival markers in patients with surgically resected non-small cell lung carcinoma.
    Moldvay J; Scheid P; Wild P; Nabil K; Siat J; Borrelly J; Marie B; Farré G; Labib T; Pottier G; Sesboüé R; Bronner C; Vignaud JM; Martinet Y; Martinet N
    Clin Cancer Res; 2000 Mar; 6(3):1125-34. PubMed ID: 10741743
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of the expression of p53, bcl-2, and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer.
    Apolinario RM; van der Valk P; de Jong JS; Deville W; van Ark-Otte J; Dingemans AM; van Mourik JC; Postmus PE; Pinedo HM; Giaccone G
    J Clin Oncol; 1997 Jun; 15(6):2456-66. PubMed ID: 9196162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology.
    Anagnostou VK; Lowery FJ; Zolota V; Tzelepi V; Gopinath A; Liceaga C; Panagopoulos N; Frangia K; Tanoue L; Boffa D; Gettinger S; Detterbeck F; Homer RJ; Dougenis D; Rimm DL; Syrigos KN
    BMC Cancer; 2010 May; 10():186. PubMed ID: 20459695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 and bcl-2 protein expression in non-small-cell lung carcinoma.
    Athanassiadou P; Dosios T; Petrakakou E; Liossi A; Zerva C; Athanassiades P
    Diagn Cytopathol; 1998 Oct; 19(4):255-9. PubMed ID: 9784987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bcl-2 expression in non-small cell lung cancers: higher frequency of expression in squamous cell carcinomas with earlier pT status.
    Dosaka-Akita H; Katabami M; Hommura H; Fujioka Y; Katoh H; Kawakami Y
    Oncology; 1999 Apr; 56(3):259-64. PubMed ID: 10202283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. bcl-2 and p53 protein expression in non-small cell lung cancers: correlation with survival time.
    Ohsaki Y; Toyoshima E; Fujiuchi S; Matsui H; Hirata S; Miyokawa N; Kubo Y; Kikuchi K
    Clin Cancer Res; 1996 May; 2(5):915-20. PubMed ID: 9816250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer.
    Fujino M; Dosaka-Akita H; Harada M; Hiroumi H; Kinoshita I; Akie K; Kawakami Y
    Cancer; 1995 Dec; 76(12):2457-63. PubMed ID: 8625071
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cell proliferation and apoptosis in stage III inoperable non-small cell lung carcinoma treated by radiotherapy.
    Langendijk H; Thunnissen E; Arends JW; de Jong J; ten Velde G; Lamers R; Guinee D; Holden J; Wouters M
    Radiother Oncol; 2000 Aug; 56(2):197-207. PubMed ID: 10927139
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of smoking with apoptosis-regulated proteins (Bcl-2, bax and p53) in resected non-small-cell lung cancers.
    Hanaoka T; Nakayama J; Mukai J; Irie S; Yamanda T; Sato TA
    Int J Cancer; 2001 Jan; 91(2):267-9. PubMed ID: 11146457
    [No Abstract]   [Full Text] [Related]  

  • 17. BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer.
    Gessner C; Liebers U; Kuhn H; Stiehl P; Witt C; Schauer J; Wolff G
    Eur Respir J; 2002 Jan; 19(1):134-40. PubMed ID: 11843312
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 accumulation associated with bcl-2, the proliferation marker MIB-1 and survival in patients with prostate cancer subjected to watchful waiting.
    Borre M; Stausbol-Gron B; Overgaard J
    J Urol; 2000 Sep; 164(3 Pt 1):716-21. PubMed ID: 10953132
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to refine N2 staging? cN2α and cN2β based on local regional involvement provide a more accurate prognosis in surgically treated IIIA non-small-cell lung cancer than N2 alone or the number of node stations involved.
    Matsunaga T; Suzuki K; Takamochi K; Oh S
    Eur J Cardiothorac Surg; 2014 Jul; 46(1):86-91. PubMed ID: 24321998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis bcl-2 and p53 expression and their relation to tumour stage in non-small cell lung carcinomas (NSCLC).
    Kargi HA; Aktaş S; Sagol O; Ermete S; Akpinar O; Akkoçlu A
    Cancer Lett; 1997 Jun; 116(2):185-9. PubMed ID: 9215862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.